CSL Total Change in Assets/Liabilities 2017-2024 | CSLLY

CSL total change in assets/liabilities for the twelve months ending December 31, 2024 was $-3.044B, a 83.56% increase year-over-year.

  • CSL annual total change in assets/liabilities for 2024 was $-1.142B, a 80.98% increase from 2023.
  • CSL annual total change in assets/liabilities for 2023 was $-0.631B, a 11.38% decline from 2022.
  • CSL annual total change in assets/liabilities for 2022 was $-0.712B, a 495.34% decline from 2021.

CSL Total Change in Assets/Liabilities 2017-2024 | CSLLY

  • CSL annual total change in assets/liabilities for 2024 was $-1.142B, a 80.98% increase from 2023.
  • CSL annual total change in assets/liabilities for 2023 was $-0.631B, a 11.38% decline from 2022.
  • CSL annual total change in assets/liabilities for 2022 was $-0.712B, a 495.34% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.3B
Amgen (AMGN)$153.1B
Gilead Sciences (GILD)$137.2B
Vertex Pharmaceuticals (VRTX)$99B
Bristol Myers Squibb (BMY)$91.2B
GSK (GSK)$75B
Regeneron Pharmaceuticals (REGN)$59.9B
Alnylam Pharmaceuticals (ALNY)$56.1B
Argenex SE (ARGX)$41.2B
BioNTech SE (BNTX)$26.8B
Insmed (INSM)$21.1B
Royalty Pharma (RPRX)$20.9B
Biogen (BIIB)$19B
Incyte (INCY)$15.2B
Illumina (ILMN)$14.5B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.8B
BioMarin Pharmaceutical (BMRN)$11.6B
Ascendis Pharma (ASND)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
QIAGEN (QGEN)$10.6B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.8B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Bio-Techne Corp (TECH)$7.8B
Halozyme Therapeutics (HALO)$7.7B
Legend Biotech (LEGN)$6.9B